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Abstract.  PECAM-1  is a recently described member 
of the immunoglobulin gene (Ig) superfamily that is 
expressed on the surface on platelets,  several leukocyte 
subsets, and at the endothelial cell intercellular junc- 
tion.  Recent studies have shown that the extracellular 
domain of PECAM-1, which is comprised of 6 Ig-like 
homology units,  participates in mediating cell-cell ad- 
hesion, plays a role in initiating endothelial cell con- 
tact,  and may later serve to stabilize the endothelial 
cell monolayer. PECAM-1  also has a  relatively large 
108 amino acid cytoplasmic domain,  with potential 
sites for phosphorylation,  lipid modification,  and other 
posttranslational  events that could potentially modulate 
its adhesive function or regulate its subcellular 
distribution.  Virtually nothing is known about the con- 
tribution of the intracellular  region of the PECAM-1 
molecule to either of these cellular processes. Using 
human platelets as a model, we now demonstrate that 
PECAM-1 becomes highly phosphorylated in response 
to cellular activation,  and coincident with phosphor- 
ylation associates with the cytoskeleton of activated, 
but not resting, platelets. The engagement of PECAM-1 
with the platelet cytoskeleton enables it to move large 
distances within the plane of the membrane of fully- 
spread,  adherent platelets.  This redistribution may 
similarly account for the ability of PECAM-1  to local- 
ize to the intracellular borders of endothelial cells 
once cell-cell contact has been achieved. 
p 
LATELET endothelial  cell  adhesion  molecule-1 
(PECAM-1) ~ is  a  130-kD  membrane  glycoprotein 
that  is expressed on the surface of human platelets 
(32),  both large  and  small  vessel  endothelium  (2,  8,  30), 
monocytes and neutrophils  (46),  and on certain T-cell sub- 
sets (4, 47). mAb cross-reactivity studies  (32) have shown 
that  PECAM-1  is identical  to the previously serologically 
defined  CD31  differentiation  antigen  (20)  which has been 
used for a number of years as a marker of myelomonocytic 
differentiation  (6, 13, 25, 34). PECAM-1 has not been found 
outside the vasculature. 
Molecular cloning of the eDNA encoding PECAM-1 (32, 
46)  has  revealed  that  this  molecule is  a  member of the 
broadly distributed Ig gene superfarnily, and contains within 
its extracellular  domain six Ig-like homology units of the C2 
subclass that  are  typical of Ig-superfamily  members that 
function  as cell-cell adhesion molecules (CAMS).  At least 
40%  of the molecular mass of PECAM-1  is composed of 
1. Abbreviations used in this  paper: CAM, cell adhesion molecule; PECAM-1, 
platelet endothelial cell adhesion molecule-l. 
complex carbohydrate residues, all of which are predicted to 
lie outside the cell. On the other side of its 19-amino acid 
transmembrane  domain,  PECAM-1  is predicted to have a 
long  cytoplasmic  domain  consisting  of  108  amino  acid 
residues, including numerous serine, threonine,  and tyrosine 
residues that could potentially become phosphorylated after 
cellular  activation. 
Although the precise function of PECAM-1 is not known 
in all the cell types that express it, a number of recent investi- 
gations have shed light on its ability to function as a cellular 
CAM. Ohto and colleagues (34) produced two routine mAbs 
directed  against  an  epitope on  PECAM-1  that  interfered 
with both monocyte and neutrophil  chemotaxis toward en- 
dotoxin-activated  serum, while Albelda et al.  (1) were able 
to prevent the association  of endothelial  cells in monolayer 
culture into their typical cobblestone morphology using anti- 
endoCAM (the bovine equivalent  of PECAM-1) antibodies. 
More recently,  Albelda et al.  (2) showed that PECAM-1 is 
capable of directly mediating  aggregation  of murine L-cells 
that have been transfected  with PECAM-1 cDNA, and that 
the aggregation of the PECAM-1 transfectants  can be speci- 
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bioactive adhesive domains have been identified within the 
extracellular portion of the PECAM-I molecule: one located 
at amino acid residues  150-155,  which corresponds  to a 
heparin-binding consensus sequence in Ig-loop 2, and the 
other defined by the epitopes of the murine mAbs PECAM- 
1.2 and 4(36,  which bind within loop 6 of PECAM-1  (the 
Ig homology domain most proximal to the membrane) (De- 
Lisser,  H.  M.,  P.  J.  Newman, W.  A.  Muller, L.  Romer, 
C. A. Buck, and S. M. Albelda, submitted for publication). 
An interesting aspect of PECAM-1  function is its ability 
to localize to the cell-ceU borders of both endothelial cells 
(1, 27, 30, 43, 48) as well as PECAM-l-transfected COS-7 
cells (2). Both of  these cell types grow as monolayers of cells 
that continue to divide in culture until they reach confluence, 
at which point cell growth is arrested by an as yet incom- 
pletely understood contact inhibition process. The subcellu- 
lar distribution of PECAM-1  in these two cell types is such 
that it remains diffusely distributed on the cell surface until 
cell-cell contact is achieved, at which point PECAM-1  be- 
comes intensely localized to the intercellular junctions. 
The mechanism by which PECAM-1  becomes  concen- 
trated at the intercellular junction is not known. It is possible 
that individual PECAM-1  molecules simply diffuse within 
the plane of  the membrane until they contact a counter recep- 
tor or ligand on an adjacent cell, at which point an adhesive 
interaction  is  achieved that prevents  further  diffusion of 
PECAM-1.  The net effect of such a mechanism would be a 
gradual accumulation of PECAM-1  at the borders of cells 
that contact each other. Alternatively, cell surface PECAM-1 
might be actively transported to the intercellular junction 
when cell contact is made. Either mechanism could provide 
for the stabilization of the junctional complex, which could 
in turn prevent further cell migration or disruption of  the cell 
monolayer.  However,  an  understanding of the  molecular 
events that regulate the subcellular distribution of this adhe- 
sive CAM would be expected to shed considerable light on 
the mechanisms that control cell-cell adhesion events that 
are important to such processes as endothelial cell migra- 
tion, wound healing, metastasis, and angiogenesis. 
Using a platelet model, we demonstrate in this manuscript 
that PECAM-1 is rapidly phosphorylated in response to cel- 
lular activation, and that coincident with the activation pro- 
cess, becomes associated with the platelet cytoskeleton. Fi- 
nally, we provide evidence that PECAM-1  redistributes in a 
cytoskeleton-dependent fashion within  the  membrane  of 
surface-activated  human platelets except at points of intercel- 
lular contact, where it instead remains at the cell-cell bor- 
der, reminiscent of its junctional localization in confluent hu- 
man endothelial cell monolayers. 
Materials and Methods 
Antibodies 
The following murine anti-human PECAM-1  mAbs were used:  hec7, an 
IgG2A antibody that has previously been shown to react with PECAM-1 at 
the endothelial cell borders (2, 30, 32), and PECAM-1.3, an IgGl antibody 
that binds PECAM-1  in both intact cells and on reduced  or nonreduced 
Western blots (2). The rabbit polyclonal  antibody,  SEW-16, was raised by 
once-weekly  subdermal  injections of  100-~g  doses  of immunoaflinity- 
purified PECAM-1  antigen.  The IgG fraction was purified  using protein 
A-Sepharose chromatography,  and had specificity  for PECAM-1 that was 
equivalent to that of the mAb. Previously described anti-GMP-140 (P-selec- 
tin) and anti-OPHb-RIa polyclonal antibodies (44, 52) were affinity purified 
and stored in 10 mM Tris, 150 mM NaCI, pH 7.4, at -70~  before use. 
Preparation ofJ2P-labeled Platelets 
Fresh human platelets were isolated from healthy aspirin-free adults as pre- 
viously described (11) except that 50 ng/ml Prostaglandin I2 (Sigma Chem- 
ical Co., St. Louis, MO) was included during the washing procedure and 
platelets  were  resuspended in a  Ca2+IMg2+/PO4-free Tyrodes  buffer  (12 
rnM NaHCO3,  138 mM NaCI,  5.5 mM glucose, 2.9 mM KCI,  50 mM 
Hepes, pH 7.35) at a concentration of I  ￿  109 platelets/ml. Washed plate- 
lets were incubated with 1.0 mCi of 32pi (carrier-free; ICN Biomedicals, 
Inc., Irvine, CA)Iml at 37~  for 4 h. 32p-labeled platelets were sedimented 
by centrifugetion and resuspended in Ca2+IMg2+/PO4-free Tyrodes buffer 
at a  concentration of 1.5  ￿  10Slml. After incubation with 0.I  Ulml of 
thrombin (kindly supplied by John Fenton If, New York State Department 
of Health, Albany, NY), 3 rain, 37~  platelets were lysed by the addition 
of an equal volume of ice-cold lysis buffer (2% Triton X-100, 20 m_M Tris, 
2  mM  sodium  metavanadate,  40  mM  molybdic acid,  80 mM  sodium 
pyrophospbate,  40 mM KH2PO+, 4 mM EGTA,  0.2 mM trifluoperazine, 
0.2 mM leupeptin, 2 mM PMSF, 0.2 Ulml hirudin [Sigma Chemical Co.], 
pH 7.1). After centrifugation (12,000 g, I0 rain) to sediment the insoluble 
cytoskeletal proteins, the supernatant was passed through a l-rnl column of 
glycine/Affigel  10  (Bio-Rad  Laboratories,  Richmond,  CA)  to  remove 
nonspecific binding proteins. The flow-through was then applied to a 0.2-ml 
column consisting of PECAM-I.3-Affigel  I0 beads (coupled at 2.5 rag anti- 
body per ml gel according to the manufacturer's directions) to isolate plate- 
let PECAM-I.  After washing (150 mM NaCl, 0.1% Triton X-100, 0.02% 
NAN3, 20 mM Tris, pH 7.4, 25 ml) PECAM-I was elnted in 0.5-ml frac- 
tions with 0.1% Triton X-100, I00 mM glycine,  pH  12.5. Peak fractions 
were identified by Cerenkov counting and precipitated by the addition of 
TCA (15% final concentration) with 20 pg of BSAltube added as a carrier. 
The TCA insoluble material was dissolved  in Laemmli SDS sample buffer 
containing 10%/~-mercaptoethanol (100~  5 rain). 32p-labeled PECAM-I 
was  resolved  by electrophoresis  on 7.5%  SDS-polyacrylamide gels and 
visualized  by autoradiography. 
Phosphoaminoacid Analysis 
32p-labeled PECAM-1  was  excised  from SDS-polyacrylamide gels  and 
homogenized in 1 ml of 0.5 M ammonium bicarbonate, 0.1% (wt/vol) SDS, 
and 1% (vol/vol)/3-mercaptoethanol.  The homogenate was centrifuged,  and 
the protein in the supernatant was precipitated by the addition of TCA to 
a final concentration of 15%, with 30/zg of BSA added as a carrier.  The 
TUA-insoluble material was washed once with ethanol/ether (1:1) and in- 
cubated in 5.7 M HCI for I h at 110~  The sample was lyophilized to re- 
move the HC1 and dissolved in H20 containing 1 mg/ml each of unlabeled 
phosphoserine, phosphothreonine, and phosphotyrosine. The sample was 
spotted onto cellulose TLC plates (Eastman Kodak Co., Rochester, NY) and 
separated by electrophoresis and chromatography,  as described by Cooper 
etal. (7) In brief, the samples were electrophoresed at 500 V for 75 rain 
in 88%  formic acid/acetic acid/H20, pH  1.9 (50:156:1794  vol/vol).  The 
plates were  dried at room temperature and chromatographed (isobutyric 
acid: 0.5 M ammonium hydroxide, 5:3 vol/vol). After autoradingraphy,  the 
32P-labeled samples were  identified  by their comigration with standards 
stained with ninhydrin. 
Preparation of  Platelet Membranes, Cytosols, 
and Cytoskeletons 
Fresh human platelets were prepared by gel filtration, and resuspended in 
gel filtration buffer (GFB; 123 mM NaCI,  12.2 mM NaCitrate,  9.9 mM 
Tris,  5.6 mM Dextrose,  2 mM Hepes,  2.8 mM KC1, 8.9 mM NaH2CO3, 
0.86 mM CaCI2, pH 7.3) at a concentration of 2-4 ￿  109/ml, as previously 
described (18, 40).  Platelet suspensions were  preincubated for 5 rain at 
37~  and then incubated 45 s further with or without 5 U/mi thrombin. 
Incubations were terminated by addition of an equal volume of lysis buffer 
containing 2% Triton X-100,  100 mM Tris-Cl,  10 mM EGTA, 0.4 mM 
leupeptin,  and 0.2 mM sodium vanadate,  pH 7.4. This procedure resulted 
in complete platelet lysis, as gauged by the release of lactate dehydrogenase 
to the 100,000 g  supernatant (>98%). Two Triton X-100-insoluble frac+ 
tions and a soluble fraction were separated by successive centrifugations  at 
4~  4 rain at 15,460 g (15-kD pellet), followed by 100,000 g for 3 h (100- 
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times in GFB and finally resuspended in GFB containing 0.2 mM leupeptin, 
1 mM Na3VO4 in a volume equal to that of the supernatant. Resuspension 
was achieved with the aid of sonication on ice. Fractions were aliquoted and 
stored at -70~ 
Platelet membrane and cytosol were prepared by suspending washed 
platelets (10~~  in a hypotonic  buffer composed of 10 mM Hepes, pH 
7,0, 1 mM EGTA, 1 mM NaH2PO4, 1 mM Na3VO4, 0.2 mM leupeptin, 5 
/zg/mi antipain, and 50/zM DTT, and sonicating on ice (3  x  10 s). Un- 
broken platelets were removed  by centrifugation at 4500 rpm for 5 min at 
4~  The  membrane-rich supernatant was  subsequently centrifuged at 
100,000 g for 90 min at 4~  The membrane pellet was washed four times 
with hypotonic  buffer  and resuspended to the original volume in this buffer 
with the aid of sonication on ice. 
Aliquots from equal numbers of platelets were mixed with Laemmli 
buffer, boiled, and resolved on 7.5 % SDS-polyacrylamide  gels. After elec- 
trophoretic transfer to nitrocellulose, membranes were blocked and then 
blotted with 25 #g/ml of SEW-16  anti-PECAM-1 polyclonal  antibody  or 50 
#g/ml of PECAM-1.3  mAb. Bound antibodies were visualized and quanti- 
tated with 1251-protein  A (for SEW-16) (19) or rabbit anti-mouse IgG fol- 
lowed by t251-protein A (PECAM-1.3), followed by autoradiography and 
gamma counting of excised bands. Quantitation was performed in a range 
where 125I-protein  A binding was determined to be linear with respect to 
platelet protein. 
Immunoelectron Microscopy 
Colloidal gold granules were prepared and conjugated to anti-PECAM-1 
mAbs using methods that have been previously described (23). Platelets ob- 
tained from normal, healthy volunteers were collected into 10 mM EGTA 
and  purified  by  differential centfifugation and  gel  filtration  through  a 
Sepharose CL-2B column into Ca2+-free  Tyrodes buffer.  Platelets were 
then deposited onto Formvar filmed Ni maxiform grids and allowed to settle 
and spread for  15 rain at 37~  The grids were then either fixed in  1% 
glutaraldehyde, 0.2% tannic acid and incubated with anti-PECAM-l-gold 
for an additional 10 rain at 37~  or incubated with anti-PECAM-I gold 
and then fixed. Samples were then postfixed, subjected to critical-point dry- 
ing,  and coated with a thin layer of carbon before examination with the 
Hitachi $900 high-resolution field emission scanning electron microscope 
(Hitachi Scientific Instruments, Mountain View, CA) of the Madison High 
Voltage Electron Microscopy facility (Madison, WI) (23). 
Results 
Phosphorylation of  PECAM-I in Resting and 
Thrombin-activated Platelets 
Since phosphorylation of the cytoplasmic domain is one of 
several ways to modify the cellular associations made by a 
membrane  glycoprotein,  experiments  were  performed  to 
evaluate whether PECAM-1 is phosphorylated under resting 
conditions,  and  whether  the  degree  of  phosphorylation 
changes after cellular activation. As shown in Fig. 1, platelet 
PECAM-1  is  indeed phosphorylated to a  limited  extent in 
resting, control platelets.  This finding is qualified by the ac- 
knowledged uncertainty that platelet preparation and wash- 
ing could have resulted in a small degree of inadvertent acti- 
vation,  in spite of the presence of PGI2 and the absence of 
added calcium or magnesium ions. Upon platelet activation, 
however,  a  significantly  increased  amount of 32p becomes 
incorporated  into  PECAM-1  (lane  T).  Quantitation  of 32p 
incorporation by densitometric scanning of lanes R (resting) 
and T(thrombin activated), as well as by excision and count- 
ing  of the  labeled,  immunoprecipitated  PECAM-1  bands 
from the gel, revealed that the level of PECAM-1 phosphory- 
lation increases  four- to fivefold after exposure of platelets 
to thrombin  (Fig.  1) and increases  two- to threefold in re- 
sponse to phorbol myristate acetate  (not shown). 
Molecular  cloning  of PECAM-1  cDNA  has  previously 
Figure 1.  Phosphorylation of 
PECAM-1 in resting and throm- 
bin-activated platelets. Washed 
haman  platelets  were  resus- 
pended  in a  Ca2+/Mg2+/po4  - 
free Tyrodes buffer and labeled 
with  32po4 for 4  h  at  37"C. 
Aliquots of 2.5  ￿  l0  s plate- 
lets  were  incubated  with 0.1 
U/ml  thrombin  or  control 
buffer for 3 min under nonstir- 
ring,  nonaggregating  condi- 
tions. Reactions were stopped 
by the addition of lysis buffer 
containing inhibitors of phos- 
phatases,  kinases,  and  pro- 
teases,  as described in Mate- 
rials and Methods. PECAM-1 
was  affinity  isolated  from 
Triton lysates  with PECAM- 
1.3/Affigel  10 beads,  eluted, 
separated by SDS-PAGE, and 
exposed  to  x-ray  film  for 
autoradiography.  (lane  R) 
PECAM-I from resting plate- 
lets.  (lane  T) PECAM-1 from 
thrombin-stimniated  platelets. 
shown  that  the  108-amino  acid  cytoplasmic  domain  of 
PECAM-1  contains  5  tyrosine,  5  threonine,  and  12 serine 
residues (32), all of which potentially could serve as sites of 
phosphate modification. To determine which of these might 
become phosphorylated upon platelet activation, the radio- 
active band shown in lane T of Fig.  1 was excised from the 
gel, homogenized, hydrolyzed in 5.7 M  HCI, and subjected 
to  phosphoamino  analysis  using  thin-layer  electrophore- 
sis/chromatography.  All of the detectable 32p was found to 
be incorporated into serine residues.  (Fig.  2). 
Figure 2. Phosphoamino acid 
analysis  of  human  platelet 
PECAM-1. ~2P-PECAM-1 was 
immunoaffinity  isolated  from 
thrombin-activated  platelets, 
acid hydrolyzed, and analyzed 
by  two-dimensional  electro- 
phoresis as described in Mate- 
rials and Methods. The circles 
show the positions ofphospho- 
serine (PS), phosphothreonine 
(PT),  and  phosphotyrosine 
(PY)  standards that were run 
simultaneously with the radio- 
labeled sample. The standards 
were detected  with  ninlaydrin,  and the  32p phosphoamino acids 
were subsequently  revealed by autoradiography of the same cellu- 
lose plates. 
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Human Platelets 
Determined  Determined  Percent PECAM-1 
Platelet  Fraction  with SEW-16  with PECAM-1.3  of total protein 
%  %  % 
Membrane  90.6  93.1  1.9 
Cytosol  9.4  6.9  0.18 
Membranes and cytosois were prepared by hypotonic lysis and sonication of 
washed human platelets, and separated by centrifugation at 100,000 g  for 90 
rain at 4"C. After SDS-PAGE and Western transfer, PECAM-I was detected 
using anti-PECAM-  1 antibodies SEW- 16 (polyclonal) or PECAM-  1.3 (mono- 
clonal).  Bound antibody was visualized and then quantitated using mI pro- 
tein A (for SEW-16) or rabbit anti-mouse IgG followed by m~sI  protein A (for 
PECAM-I.3),  autoradiography, and gamma counting of excised bands (19). 
Association of  PECAM-1 with the Cytoskeleton of 
Thrombin-activated Platelets 
Of the numerous glycoproteins present on the platelet sur- 
face, only the GPlIb-IRa complex has been found to become 
specifically associated with the cytoskeleton after thrombin 
activation (36,  38,  49).  Like PECAM-1,  GPIIIa becomes 
phosphorylated upon platelet activation (37), though to only 
a  limited extent (15).  Preliminary studies established that 
>90% of total platelet PECAM-1  is found within the platelet 
membrane (Table I). To examine whether this PECAM-1  is 
associated with the cytoskeleton  in either resting or activated 
platelets, Triton-insoluble residues were prepared and exam- 
ined for PECAM-1 content by both immunoprecipitation and 
Western  blot  analysis.  As  shown  in  Fig.  3,  most of the 
PECAM-1  ('~90%) was found in the soluble fraction of rest- 
ing platelets, with little detectable PECAM-1  in the 15-kD 
cytoskeleton,  and  ,o10%  associated  with  the  membrane 
Figure 3. Association of PECAM-1 with the cytoskeleton of  throm- 
bin-aggregated platelets. Resting or thrombin-aggregated  platelets 
were lysed in 1% Triton X-100, and the two Triton-insoluble frac- 
tions, as well as the soluble supernatant, were isolated by ditferen- 
tial centrifugation as described in Materials and Methods. Proteins 
from the indicated subceUular fractions were electrophoresed, im- 
munoblotted with the polyclonal anti-PECAM-1 antibody SEW-16, 
detected with I~I protein A, and visualized by autoradiography. 
(C) 15,000 g cytoskeletal pellet; (M) 100,000 g membrane skel- 
eton; and (S) "lYiton-soluble  supernatants. Note the profound shift 
of PECAM-1 from the soluble fraction of resting platelets into the 
15-kD cytoskeleton of thrombin-activated cells. 
Table II. Distribution of PECAM-1 in Triton-lysed 
Platelet Fractions 
Sub-cellular fraction 
Thrombin-activated 
Resting platelets  platelets 
PECAM-1  (protein)  PECAM-1 (protein) 
15-kD cytoskeleton 
100-kD  membrane skeleton 
Triton-soluble fraction 
(%)  (%) 
0.9 + 0.6 (19)  64.0  -i- 1.6 (38) 
10.9 +  1.0 (15)  1.6 + 0.6 (9) 
88.2 +  0.4  (66)  34.4  +  2.2  (53) 
Platelet  suspensions were incubated at 37~  with (activated)  or without (rest- 
ing) thrombin, and then lysed with an equal volume of lysis buffer containing 
2% Triton X-100 and 10 mM EGTA. Two Triton-insoluble residues as well 
as the Triton-soluble fraction were isolated by differential  centrifugation as 
described in Materials and Methods. The amount of PECAM-1 in each of these 
subceilular fractions was determined as described in Table I. The percentage 
of total protein (in parenthesis) in each fraction was determined using a stan- 
dard colorometric protein assay. 
skeleton (10). However, when the platelets were aggregated 
with  thrombin,  a  dramatic  increase  in  the  amount  of 
cytoskeletally associated PECAM-1  was found (Fig. 3). Ex- 
cision of the radiolabeled bands identifying PECAM-1  al- 
lowed an estimation of the distribution of PECAM-1  among 
the  various  subcellular  fractions in  both  resting  and  ag- 
gregated conditions (Table II). From these experiments we 
determined that 'x,64%  of membrane-bound PECAM-1  be- 
comes associated with the 15-kD Triton-insoluble cytoskele- 
ton  upon  platelet aggregation.  Control experiments  were 
also carded out that examined the subcellular distribution 
of GPlIb-llIa  and  GMP-140  (P-selectin)  in parallel  with 
PECAM-1. As shown in Fig. 4, although both the GPlIb-lIIa 
complex and PECAM-1  cosedimented with the 15-kD cyto- 
skeleton of activated, but not resting platelets,  GMP-140, 
which is also a transmembrane glycoprotein (17, 28, 45), did 
not cosediment with the cytoskeleton. These results demon- 
strate that the 15-kD pellet containing PECAM-1 did not re- 
sult from nonspecific trapping of this membrane glycopro- 
tein or from incompletely solubilized and pelleted membrane 
fragments. 
Functional Redistribution of  PECAM-1 with the 
Platelet Cytoskeleton 
To see whether the biochemically demonstrated linkage with 
the platelet cytoskeleton represents an actual functional as- 
sociation, we next investigated the whole-cell distribution of 
PECAM-1  on the surface of the human platelets that had be- 
come activated by allowing them to spread on formvar sur- 
faces. High-resolution scanning EM was used to visualize 
directly  gold-conjugated  anti-PECAM-1  mAbs  that  had 
been incubated with either glutaraldehyde-fixed or unfixed, 
fully spread platelets. This method has previously been ex- 
ploited to show sequential changes in the three-dimensional 
organization of the platelet cytoskeleton (24),  and to show 
ligand- or antibody-triggered, cytoskeletally directed, cen- 
tralization  of GPRb--HIa.  (23).  Preliminary  studies  (not 
shown)  established  that  pseudopodial  platelets  in  early 
stages of activation and spreading were labeled evenly across 
their surfaces with anti-PECAM-1  immunogold particles. 
As shown in Fig.  5, PECAM-1 remains evenly distributed on 
the surface of fully spread, fixed platelets (A), but is actively 
transported in the plane of the membrane toward the center 
of unfixed cells once the cytoskeleton has redistributed after 
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insoluble cytoskeletons from resting and aggregated  platelets were 
prepared from 10 ml of washed platelets (2.5-5  x  108/ml) which 
had been incubated in the presence or absence of  0.1 U/ml of  throm- 
bin for 5 min at 37~  with constant stirring. An equal volume of 
cold Triton lysis buffer (0.1 M Tris, 0.01 M EGTA, 2% [wt/vol]  Tri- 
ton X-100, pH 7.4, containing 400 ~g/ml of leupeptin and 1 mM 
PMSF) was then added and the samples processed for electropho- 
resis as described in Materials and Methods. 50 gg of protein was 
loaded per lane. Protein bands were revealed using either affinity- 
purified anti-PECAM-1 (A), anti-GP llb-IIIa (B), or anti-GMP- 
140 (C) polyclonal antibodies (5 t~g/ml, final concentration), and 
~25I-labeled goat anti-mouse IgG (1 ~g/ml; 106 dpm/ml) with sub- 
sequent autoradiography. Control experiments confirmed that gly- 
coprotein quantitation was linear over the range evaluated by this 
technique in these experiments. Whole platelets (lane 1), resting 
platelet cytoskeletons (lane 2), and thrombin aggregated platelet 
cytoskeletons (lane 3). 
surface activation (B). Interestingly, although the majority 
of the anti-PECAM-1  gold particles moved away from the 
periphery of the cell, some remained localized at sites of 
platelet-platelet contact (Fig. 5, C and D), reminiscent of its 
enriched distribution at the intercellular junctions of adja- 
cent endothelial cells (2,  30, 32). Whether or not the sub- 
population of  PECAM-1 that remains at the site of interplate- 
let contact functions to stabilize the platelet aggregate is not 
known. 
Discussion 
The purpose of the present investigation was to determine 
whether PECAM-I  is capable of forming transmembrane 
connections with the underlying cytoskeleton in response to 
a  cellular activation event, and whether PECAM-1  can be 
found to  redistribute  within the  plasma  membrane  in  a 
cytoskeleton-directed  manner.  Both  of  these  issues  are 
difficult to address experimentally in monolayer cells be- 
cause they remain tightly attached to an extracellular matrix 
and are themselves difficult to activate and then solubilize 
effectively.  Therefore, we exploited the fact that PECAM-1 
is also expressed on the surface of human platelets, a cell 
type that is  extremely amenable to  studies of activation- 
dependent events, as they can be easily transformed from 
resting, nonadherent single cells into active, adhesive ag- 
gregates. Moreover, the cytoskeletal  elements ofplatelets are 
well defined and are relatively easy to obtain in purified 
form. Our approach was based in part on that adopted by 
Phillips et ai. (38), who showed more than 12 years ago that 
while most cellular proteins are solubilized by the addition 
of nonionic detergents,  the platelet cytoskeleton remains 
Triton X-100 insoluble. Membrane proteins that participate 
in cell-cell  adhesion can likewise be rendered detergent- 
insoluble providing that they become associated with cyto- 
skeletal structures within the cell. 
Phosphorylation is one of several potential posttransla- 
tional modifications that could modulate the subcellular dis- 
tribution and adhesive activity of PECAM-1,  and thus it was 
of considerable interest that PECAM-1 was found to become 
highly phosphorylated after platelet stimulation. Although 
PECAM-1  shares considerable sequence identity with the 
PDGF receptor in the cytoplasmic tail (32),  and also con- 
talns a number of tyrosine residues located in a favorable en- 
vironment for phosphorylation, phosphate was found to be 
incorporated only on serine residues. A two- to threefold in- 
crease in phosphorylation  of  cytoplasmic serine residues was 
found after activation with PMA, while a four- to fivefold in- 
crease was achieved using thrombin as the agonist. It seems 
likely that protein kinase C (PKC) mediates, at least in part, 
the phosphorylation of PECAM-1, since both thrombin and 
PMA are known to induce PKC activation in platelets (37, 
41), and PKC is a serine- or threonine-specific enzyme (33). 
The differences in degree of phosphorylation induced by 
thrombin versus PMA suggest that other kinases,  such as 
CA2+/calmodulin kinase (26) may also be involved. Further 
studies will be required to determine the complement of cel- 
lular kinases that may be responsible for phosphorylating 
PECAM-1. 
In resting platelets, a majority of the GPIb/V/IX complex, 
as well as the GPIa-IIa collagen receptor, exist preassociated 
with a membrane skeleton (9, 10) that is largely composed 
of actin, actin-binding protein, and spectrin (14). In contrast, 
<5%  of the  GPllb-Illa  complex  (49),  and  only  1%  of 
PECAM-1  (this study) are linked to the cytoskeleton in rest- 
ing cells.  These differences may reflect the role of GPIb/ 
V/IX and GPIa-IIa in mediating cell-matrix, versus cell-cell 
interactions, as platelet-collagen interactions occur initially 
with resting cells, while cell-cell contact develops only after 
cellular activation of some type. After aggregation of plate- 
lets with thrombin, however, >60% of platelet PECAM-1 be- 
came associated with the 15-kD cytoskeleton (Pig.  3, Table 
II). This is proportionally '~2-3 times the amount of GPIIb- 
Ifia that becomes cytoskeletally associated after thrombin- 
(20 %) (38) or arachidonic acid- (28 %) (49) induced platelet 
aggregation. The physiological significance of the associa- 
tion of either GPIlb-HIa or PECAMq with the cytoskeleton 
is unclear, but it has been speculated that only those proteins 
directly mediating the interactions between cells become in- 
corporated into the cytoskeleton in such a manner (38) (dis- 
cussed further below). The fact that none of the other 20 or 
more platelet membrane glycoproteins have been found to 
cosediment with the 15-kD cytoskeleton  of aggregated plate- 
lets speaks to the functional specificity and potential signifi- 
cance of this event. 
Whether PECAM-1  actually becomes associated with the 
platelet cytoskeleton as a result of its phosphorylation re- 
mains to be determined, as incorporation of radiolabeled 
phosphate into PECAMq, and PECAM-I's parallel incorpo- 
ration into the cytoskeleton are merely correlative events at 
this time. Preliminary studies suggest that the stoichiometry 
Newman et al. Activation-dependent Changes in PECAM-1  243 Figure 5. (.4 arid B) Redistribution of PECAM-1 with the platelet cytoskeleton of fully spread platelets. (,4) Platelets were allowed to spread 
onto a Formvar grid for 15 rain at 37~  and then were fixed with 1%  glutaraldehyde, 0.2% tannic acid. Anti-PECAM-1 gold particles 
were then used to visualize PECAM-1  on the platelet surface. Note the even distribution of gold particles. The light region at the center 
is due to upward protrusion of the platelet granulomere, and is not antibody enriched. (B) Fully spread, unfixed platelets were labeled 
with anti-PECAM-1/gold and incubated for an additional 10 rain at 37~  Note the large concentration of gold particles at the center (small 
arrows) and the relative  absence of particles at the periphery (/arge arrows). (C and D) Localization  of  platelet PECAM-1 to sites of intercel- 
lular contact.  Fields illustrate overlapping regions of adjacent platelets at sites of interaction. Arrows indicate zones of concentrated 
anti-PECAM 1/18-rim gold particles that are representative of multiple fields observed. Antibodies to GPIlb-IIIa  showed similar distribu- 
tion, while control antibodies to GPIb-IX complex did not become similarly localized. (C)  ￿  20,000;  (D)  ￿  30,000. 
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and P. J.  Newman, manuscript  in preparation),  suggesting 
that all PECAM-1 molecules that associate with the cytoskel- 
eton  may  in  fact be phosphorylated  first.  Future  studies 
aimed at identification of the precise serine residue(s) within 
the  cytoplasmic  domain  that  become phosphorylated,  as 
well as site-specific prevention of its phosphorylation,  will 
be helpful in establishing the role, if any, of phosphoserine 
residues in mediating the linkage of PECAM-1 with specific 
cytoskeletal elements. 
In  addition  to  the  biochemical  evidence  of PECAM-1/ 
cytoskeletal association, we also used a morphological ap- 
proach to show that PECAM-1 is functionally linked to the 
platelet cytoskeleton. As previously pointed out by Fox et al. 
(10), protein-protein associations that are detected after de- 
tergent  lysis  could  conceivably have  occurred  during  the 
solubilization process,  highlighting  the importance  of per- 
forming correlative biochemical and morphological studies 
before drawing  conclusions regarding  the association of a 
membrane  glycoprotein with the underlying  cytoskeleton. 
At least three different types of movement of glycoprotein 
receptors within the plane of the platelet plasma membrane 
have been previously described: receptor clustering (16, 39, 
42, 51), translocation of receptors into the open canalicular 
system  (OCS)  (22),  and  centripetal  movement  of recep- 
tor/ligand  or receptor/antireceptor  complexes towards the 
center  of fully spread  platelets  (23).  Both  clustering  and 
translocation  of receptors  to  the  OCS  are  thought  to  be 
driven by the underlying membrane skeleton, and occur in- 
dependently of reorganization of the cytoplasmic cytoskele- 
ton (16, 21, 22), while centripetal redistribution of receptors 
from the platelet periphery  into  the  central  zone of fully 
spread platelets has been shown to be critically dependent on 
the presence of an intact, contractile actin cytoskeleton, and 
is abolished in the presence of both cytochalasin B (50), as 
well as cytochalasins D and E (35). Therefore, the spreading 
platelet  system  was  used  to  investigate  whether  or  not 
PECAM-1 formed a functional link with the cytoskeleton in 
intact cells.  PECAM-1  was found to be evenly distributed 
over the platelet surface in fully spread cells that had been 
fixed to prevent receptor mobility (Fig. 5 A). Anti-PECAM-1 
antibodies,  however,  triggered  a  rapid,  cytoskeletally di- 
rected redistribution of PECAM-1 from the periphery of un- 
fixed, fully spread platelets into the central region (Fig. 5 B). 
Thus,  PECAM-1, like the fibrinogen receptor,  GPIIb-IIIa, 
appears to establish a link with the underlying cytoplasmic 
actin  cytoskeleton that results  in its movement within  the 
plane of the membrane.  We postulate that PECAM-1,  like 
GP[Ib-IIIa,  may function in this manner  to direct incom- 
ing  platelets  towards  the  center  of a  developing  platelet 
thrombus, thereby organizing and consolidating the platelet 
clot (3). 
Although the majority of PECAM-1 was found to redistrib- 
ute toward the platelet granulomere,  a subset of PECAM-1 
molecules was found to remain at points of platelet-platelet 
contact (Fig. 5, C and D), suggesting that they may function 
to stabilize platelet-platelet interactions.  That these periph- 
erally localized PECAM-1  molecules do not play a major 
role in mediating platelet cohesion is evidenced by the fact 
that (a) platelets from patients with Glanzmann  thrombas- 
thenia,  which lack functional fibrinogen receptors (31) but 
express the full complement of PECAM-1 (5), are not cap- 
able of aggregating  in response to any normal  physiologic 
stimulus, and (b) anti-PECAM-1  polyclonal or monoclonal 
antibodies do not interfere significantly with the platelet ag- 
gregation process (27, 29, 34) (E J. Newman, unpublished 
observations). Future studies will be required to determine 
the function of the subpopulation of PECAM-1 that remains 
at the site of interplatelet contact. 
In summary, the major findings of the study are that:  (a) 
PECAM-1 becomes phosphorylated on serine residues upon 
cellular activation;  (b) coincident  with the activation pro- 
cess,  PECAM-1  becomes specifically  associated  with  the 
Triton-insoluble  cytoskeleton;  and  (c)  the  association  of 
PECAM-1 with contractile elements of the platelet cytoskel- 
eton results in its centralization in response to surface activa- 
tion events that take place during the platelet spreading pro- 
cess. Based upon these results, it would be of considerable 
interest to examine the effect of deleting the cytoplasmic do- 
main of PECAM-1 on its ability to localize to the intercellu- 
lar junctions of transfected fibroblasts using the system that 
we have previously described (2).  Serine to alanine muta- 
genesis within the cytoplasmic domain could also be used to 
localize precisely which serine(s) are necessary to become 
phosphorylated for cytoskeletal association to occur. Finally, 
although  PECAM-1  appears to make connections with the 
cytoskeleton, the specific cytoskeletal elements with which 
it interacts remain to be identified.  It is expected that fur- 
ther elucidation of the cellular and molecular properties of 
PECAM-1 will be important in helping us understand its role 
in vascular biology, inflammation,  wound healing,  and the 
immune response. 
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